XML 61 R44.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Summary of Stock Option Activity | A summary of the status of the options granted by Teva as of December 31, 2023, 2022 and 2021, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).
|  | Year ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
|  | Number (in thousands) |  |  | Weighted average exercise price |  |  | Number (in thousands) |  |  | Weighted average exercise price |  |  | Number (in thousands) |  |  | Weighted average exercise price |
Balance outstanding at beginning of year |  |  | 24,119 |  |  | $ | 36.83 |  |  |  | 29,015 |  |  | $ | 36.96 |  |  |  | 35,234 |  |  | $ | 37.27 |
Changes during the year: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forfeited |  |  | (885 | ) |  |  | 34.65 |  |  |  | (2,378 | ) |  |  | 33.77 |  |  |  | (3,644 | ) |  |  | 36.09 |
Expired |  |  | (531 | ) |  |  | 37.57 |  |  |  | (2,518 | ) |  |  | 41.26 |  |  |  | (2,575 | ) |  |  | 42.40 |
Balance outstanding at end of year |  |  | 22,703 |  |  |  | 36.89 |  |  |  | 24,119 |  |  |  | 36.83 |  |  |  | 29,015 |  |  |  | 36.96 |
Balance exercisable at end of year |  |  | 22,703 |  |  |  | 36.89 |  |  |  | 24,119 |  |  |  | 36.83 |  |  |  | 26,989 |  |  |  | 38.30 |
No options were granted during 2023, 2022 and 2021.
Schedule of Ordinary Shares Issued Upon Vested Options | The following table summarizes information as of December 31, 2023 regarding the number of ordinary shares issuable upon vested options:
Number of ordinary shares issuable upon exercise of vested options |
Range of exercise prices |  | Balance at end of period (in thousands) |  |  | Weighted average exercise price |  |  | Weighted average remaining life |
|  | Number of shares |  |  | $ |  |  | Years |
Lower than $15.01 |  |  | 592 |  |  |  | 11.40 |  |  |  | 3.84 |
$15.01 - $25.00 |  |  | 7,374 |  |  |  | 18.95 |  |  |  | 4.14 |
$25.01 - $35.00 |  |  | 5,470 |  |  |  | 34.66 |  |  |  | 3.17 |
$35.01 - $45.00 |  |  | 61 |  |  |  | 37.97 |  |  |  | 2.78 |
$45.01 - $55.00 |  |  | 5,707 |  |  |  | 51.26 |  |  |  | 1.36 |
$55.01 - $65.00 |  |  | 3,500 |  |  |  | 59.04 |  |  |  | 1.34 |
Total |  |  | 22,703 |  |  |  | 36.89 |  |  |  | 2.76 |
Schedule of the Number of RSUs Issued and Outstanding | The following table summarizes information about the number of RSUs and PSUs granted and outstanding:
|  | Year ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
|  | Number (in thousands) |  |  | Weighted average grant date fair value |  |  | Number (in thousands) |  |  | Weighted average grant date fair value |  |  | Number (in thousands) |  |  | Weighted average grant date fair value |
Balance outstanding at beginning of year |  |  | 32,302 |  |  | $ | 9.11 |  |  |  | 24,412 |  |  | $ | 11.58 |  |  |  | 20,720 |  |  | $ | 13.81 |
Granted |  |  | 16,608 |  |  |  | 9.77 |  |  |  | 18,755 |  |  |  | 7.42 |  |  |  | 12,748 |  |  |  | 10.42 |
Vested |  |  | (10,195 | ) |  |  | 10.28 |  |  |  | (7,571 | ) |  |  | 13.02 |  |  |  | (6,818 | ) |  |  | 15.60 |
Forfeited |  |  | (3,052 | ) |  |  | 9.81 |  |  |  | (3,293 | ) |  |  | 9.81 |  |  |  | (2,238 | ) |  |  | 12.18 |
Balance outstanding at end of year |  |  | 35,664 |  |  |  | 9.07 |  |  |  | 32,302 |  |  |  | 9.11 |  |  |  | 24,412 |  |  |  | 11.58 |
Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value | The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2023, 2022 and 2021, the Company recorded stock-based compensation costs as follows:
|  | Year ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
|  | (U.S. $ in millions) |
Employee stock options |  | $ | — |  |  | $ | 2 |  |  | $ | 16 |
RSUs and PSUs |  |  | 121 |  |  |  | 122 |  |  |  | 103 |
Total stock-based compensation expense |  |  | 121 |  |  |  | 124 |  |  |  | 119 |
Tax effect on stock-based compensation expense |  |  | 11 |  |  |  | 9 |  |  |  | 12 |
Net effect |  | $ | 110 |  |  | $ | 115 |  |  | $ | 107 |
Accumulated Other Comprehensive Income/(Loss) (Net of Tax) | The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:
|  | Net Unrealized Gains/(Losses) |  |  | Benefit Plans |  |  |  |
|  | Foreign currency translation adjustments |  |  | Derivative financial instruments |  |  | Actuarial gains/(losses) and prior service (costs)/ credits |  |  | Total |
|  | (U.S. $ in millions) |
Balance as of January 1, 2021 |  | $ | (1,919 | ) |  |  | (363 | ) |  |  | (117 | ) |  |  | (2,399 | )
Other comprehensive income/(loss) before reclassifications |  |  | (386 | ) |  |  | — |  |  |  | 18 |  |  |  | (368 | )
Amounts reclassified to the statements of income |  |  | — |  |  |  | 39 |  |  |  | 18 |  |  |  | 57 |
Net other comprehensive income/(loss) before tax |  |  | (386 | ) |  |  | 39 |  |  |  | 36 |  |  |  | (311 | )
Corresponding income tax |  |  | 31 |  |  |  | — |  |  |  | (4 | ) |  |  | 27 |
Net other comprehensive income/(loss) after tax* |  |  | (355 | ) |  |  | 39 |  |  |  | 32 |  |  |  | (284 | )
Balance as of December 31, 2021 |  |  | (2,274 | ) |  |  | (324 | ) |  |  | (85 | ) |  |  | (2,683 | )
Other comprehensive income/(loss) before reclassifications |  |  | (223 | ) |  |  | — |  |  |  | 40 |  |  |  | (183 | )
Amounts reclassified to the statements of income |  |  | — |  |  |  | 29 |  |  |  | 27 |  |  |  | 56 |
Net other comprehensive income/(loss) before tax |  |  | (223 | ) |  |  | 29 |  |  |  | 67 |  |  |  | (127 | )
Corresponding income tax |  |  | (17 | ) |  |  | — |  |  |  | (10 | ) |  |  | (27 | )
Net other comprehensive income/(loss) after tax* |  |  | (240 | ) |  |  | 29 |  |  |  | 57 |  |  |  | (154 | )
Balance as of December 31, 2022 |  |  | (2,514 | ) |  |  | (295 | ) |  |  | (28 | ) |  |  | (2,838 | )
Other comprehensive income/(loss) before reclassifications |  |  | 167 |  |  |  | (1 | ) |  |  | (17 | ) |  |  | 149 |
Amounts reclassified to the statements of income |  |  | — |  |  |  | 30 |  |  |  | (4 | ) |  |  | 26 |
Net other comprehensive income/(loss) before tax |  |  | 167 |  |  |  | 29 |  |  |  | (21 | ) |  |  | 175 |
Corresponding income tax |  |  | (37 | ) |  |  | — |  |  |  | 3 |  |  |  | (34 | )
Net other comprehensive income/(loss) after tax* |  |  | 130 |  |  |  | 29 |  |  |  | (18 | ) |  |  | 141 |
Balance as of December 31, 2023 |  | $ | (2,384 | ) |  | $ | (266 | ) |  | $ | (46 | ) |  | $ | (2,697 | )
* | Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $50 million loss in 2023, $116 million loss in 2022 and $107 million loss in 2021.

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration